Nevirapine Arrow Lab

Nevirapine, the active ingredient in Nevirapine Arrow Lab, is a Non-nucleoside reverse transcriptase inhibitor (NNRTI) presented as an oral tablet for oral use. It is employed in the treatment of HIV-1 infection in adults and adolescents, and is part of combination antiretroviral regimens.

GNH USA supplies Nevirapine Arrow Lab as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable sourcing, regulatory documentation and logistics support for bulk and unit-dose orders across multiple continents.

Nevirapine is an NNRTI used in antiretroviral therapy to suppress HIV-1 replication and is incorporated into various treatment regimens.

- HIV-1 infection (treatment-naïve adults): Decreases plasma HIV-1 RNA levels when combined with other antiretrovirals, leading to immune recovery. - HIV-1 infection (treatment-experienced patients): Provides an alternative option for patients with resistance to other drug classes. - Prevention of mother-to-child transmission: Used in selected regimens to reduce the risk of vertical HIV transmission during pregnancy and delivery.

Nevirapine may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Rash: mild to moderate skin eruption, often pruritic. - Nausea: transient gastrointestinal discomfort. - Headache: mild to moderate intensity. - Fatigue: general tiredness. - Abdominal pain: mild discomfort in the stomach area. - Dizziness: transient vertigo or light‑headedness. - Diarrhea: loose stools, usually self‑limiting. - Insomnia: difficulty falling or staying asleep.

Serious or Rare Side Effects: - Stevens‑Johnson syndrome: severe skin reaction with blistering and mucosal involvement. - Hepatotoxicity: elevated liver enzymes, hepatitis, or liver failure. - Severe hypersensitivity: fever, eosinophilia, and systemic symptoms. - Neutropenia: marked reduction in white blood cells increasing infection risk. - Liver failure: acute hepatic decompensation requiring medical intervention.

When prescribing Nevirapine, clinicians should observe several safety measures to minimize risks.

- Monitor liver function: obtain baseline transaminases and repeat periodically. - Assess for rash: discontinue if severe skin reaction develops. - Avoid co‑administration with potent CYP3A4 inducers: may reduce drug exposure. - Use caution in patients with hepatitis B or C: increased risk of hepatic toxicity. - Adjust dose in renal impairment if required by clinical judgment. - Store below 25°C: keep in the original pack, protect from moisture.

Nevirapine interacts with several medicines through metabolic pathways, requiring careful management.

Major Interactions (Avoid): - Rifampicin: strong CYP3A4 inducer that markedly lowers nevirapine levels. - St. John’s wort: herbal CYP3A4 inducer reducing antiviral efficacy. - Protease inhibitors boosted with ritonavir: may increase nevirapine concentrations and toxicity. - Carbamazepine: enzyme inducer that can diminish nevirapine exposure.

Moderate Interactions (Monitor Closely): - Efavirenz: co‑administration may increase hepatotoxic risk. - Other NNRTIs (e.g., delavirdine): additive toxicity potential. - Antacids containing aluminum or magnesium: may affect absorption if taken simultaneously. - Fluconazole: moderate CYP inhibition that can raise nevirapine levels.